Tissue Plasminogen Activator Use in Pediatric Patients: A Single Center Experience
| Autor: | Hasan Fatih Çakmaklı, Mehmet Ertem, Zümrüt Uysal, Esra Pekpak, Serap Teber Tıras, Elif İnce, Ercan Tutar, Talia Ileri, Tayfun Uçar |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Thrombolytic treatment medicine.medical_treatment Hemorrhage Single Center Tissue plasminogen activator 03 medical and health sciences 0302 clinical medicine Fibrinolytic Agents medicine Thrombolytic Agent Humans Dosing Child Cardiac catheterization business.industry Infant Thrombosis Hematology medicine.disease Surgery Cardiac surgery Oncology 030220 oncology & carcinogenesis Child Preschool Tissue Plasminogen Activator Pediatrics Perinatology and Child Health Female business 030215 immunology medicine.drug |
| Zdroj: | Journal of pediatric hematology/oncology. 43(5) |
| ISSN: | 1536-3678 |
| Popis: | Introduction Thrombosis is rare in children and antithrombolytic treatment is controversial. Most commonly used thrombolytic agent is tissue plasminogen activator (t-PA) in pediatrics. In this study, we report our experience in the use of thrombolytic treatment. Methods Eighteen patients who had received systemic t-PA between January 2006 and December 2013 were recorded. The response to t-PA was evaluated as complete, partial, and no. The bleeding complication during t-PA administration was graded as minor or major. Results There were 18 patients (2 mo to 12 y) who received systemic t-PA. Three patients had venous, 14 patients had arterial, and 1 patient had intracardiac thrombosis. Thrombosis was related to cardiac catheterization (61.1%), central venous catheterization (16.7%), cardiac surgery (11.1%), and arrhythmia (5.5%). In 1 patient thrombosis occurred spontaneously (5.5%). Eighteen patients received 25 courses of systemic t-PA (0.15 to 0.3 mg/kg/h). A total of 55.6% of cases had complete, 27.8% had partial, and 16.6% showed no resolution. Conclusion t-PA infusion at doses of median 0.2 mg/kg/h (0.15 to 0.3) seems effective and safe. There is still no consensus on indications and dosing of antithrombolytic treatment in children but in selected patients it decreases long-term complications due to thrombosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|